RecruitingNCT05450783

Tissue and Metabolic Characterization of Arrhythmogenic Cardiomyopathies by Hybrid PET-MRI Imaging, Impact of the Observed Profiles on the Phenotype and on the Evolution of Cardiomyopathy


Sponsor

Nantes University Hospital

Enrollment

80 participants

Start Date

Sep 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Status of the research project: The main complications of arrhythmogenic cardiomyopathies (AC) are sudden death, more rarely heart failure. Recently, data are emerging in favor of an associated role of myocardial inflammation and myocarditis in this pathology, but the impact of inflammation on the presentation and prognosis of the cardiomyopathy, as well as its mechanisms, are not clearly elucidated. To date, endomyocardial biopsy is the gold standard for documenting myocardial inflammation. Aim of the research: To evaluate the interest of a new hybrid PET-MR imaging tool for tissue and metabolic characterization of AC associating MRI and 18F-FDG PET, already used in inflammatory pathologies (cardiac sarcoidosis). Project description: Multicentric observational study of 80 patients with genetic AC undergoing PET-MR. Description of the observed profiles and their impact on the phenotype of the cardiomyopathy and its evolution, study of associated immunological mechanisms, correlation with available anatomopathological data. Expected results and perspectives: first non-invasive description of tissue and metabolic phenotype of AC by PET-MR imaging and its prognostic role, basis for pathophysiological and therapeutic research in case of confirmation of the performances of this imaging for the detection of myocardial inflammation.


Eligibility

Min Age: 16 YearsMax Age: 99 Years

Inclusion Criteria1

  • Male and female over 16 years old

Exclusion Criteria4

  • Patients and their relatives with left ventricular or biventricular AC and carrier of a pathogenic or likely pathogenic variant in one of the following genes : PKP2, DSG2, DSC2, JUP, DSP, DES, FLNC, PLN, LMNA, TMEM43, CDH2, BAG3, RYR2, RBM20 Consent form
  • Sarcoidosis or known or diagnosed autoimmune disease
  • History of myocardial infarction
  • Patient under guardianship, curatorship or safeguard of justice

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBiocollection

serum


Locations(5)

CHU Angers

Angers, France

CHU Brest

Brest, France

CHU de Nantes

Nantes, France

AP-HP La Salpêtrière

Paris, France

CHU de Rennes

Rennes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05450783